| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| R G Pertwe. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17828291. |
brief mention is also made in this review, first of the production by delta9-thc of pharmacodynamic tolerance, second of current knowledge about the extent to which delta9-thc, cbd and delta9-thcv interact with pharmacological targets other than cb1 or cb2 receptors, and third of actual and potential therapeutic applications for each of these cannabinoids. |
2008-04-02 |
2023-08-12 |
Not clear |
| A Arévalo-Martín, D García-Ovejero, O Gómez, A Rubio-Araiz, B Navarro-Galve, C Guaza, E Molina-Holgado, F Molina-Holgad. CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17891163. |
cb2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. |
2008-04-02 |
2023-08-12 |
Not clear |
| A Arévalo-Martín, D García-Ovejero, O Gómez, A Rubio-Araiz, B Navarro-Galve, C Guaza, E Molina-Holgado, F Molina-Holgad. CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17891163. |
cannabinoids are well known immunomodulatory molecules that act through cb1 and cb2 receptors. |
2008-04-02 |
2023-08-12 |
Not clear |
| K L Wright, M Duncan, K A Sharke. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17906675. |
cannabinoid cb2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. |
2008-04-02 |
2023-08-12 |
Not clear |
| C A Lunn, E-P Reich, J S Fine, B Lavey, J A Kozlowski, R W Hipkin, D J Lundell, L Bobe. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17906679. |
biology and therapeutic potential of cannabinoid cb2 receptor inverse agonists. |
2008-04-02 |
2023-08-12 |
human |
| C A Lunn, E-P Reich, J S Fine, B Lavey, J A Kozlowski, R W Hipkin, D J Lundell, L Bobe. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17906679. |
evidence has emerged suggesting a role for the cannabinoid cb2 receptor in immune cell motility. |
2008-04-02 |
2023-08-12 |
human |
| C A Lunn, E-P Reich, J S Fine, B Lavey, J A Kozlowski, R W Hipkin, D J Lundell, L Bobe. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17906679. |
this provides a rationale for a novel and generalized immunoregulatory role for cannabinoid cb2 receptor-specific compounds. |
2008-04-02 |
2023-08-12 |
human |
| C A Lunn, E-P Reich, J S Fine, B Lavey, J A Kozlowski, R W Hipkin, D J Lundell, L Bobe. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17906679. |
in support of this possibility, we will review the biology of a class of cannabinoid cb2 receptor-specific inverse agonist, the triaryl bis-sulfones. |
2008-04-02 |
2023-08-12 |
human |
| C A Lunn, E-P Reich, J S Fine, B Lavey, J A Kozlowski, R W Hipkin, D J Lundell, L Bobe. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17906679. |
we will show that one candidate, sch.414319, is potent and selective for the cannabinoid cb2 receptor, based on profiling studies using biochemical assays for 45 enzymes and 80 g-protein coupled receptors and ion channels. |
2008-04-02 |
2023-08-12 |
human |
| C Benito, R M Tolón, M R Pazos, E Núñez, A I Castillo, J Romer. Cannabinoid CB2 receptors in human brain inflammation. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17934510. |
cannabinoid cb2 receptors in human brain inflammation. |
2008-04-02 |
2023-08-12 |
human |
| C Benito, R M Tolón, M R Pazos, E Núñez, A I Castillo, J Romer. Cannabinoid CB2 receptors in human brain inflammation. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17934510. |
the presence of functional cannabinoid cb2 receptors in the cns has provoked considerable controversy over the past few years. |
2008-04-02 |
2023-08-12 |
human |
| S Lotersztajn, F Teixeira-Clerc, B Julien, V Deveaux, Y Ichigotani, S Manin, J Tran-Van-Nhieu, M Karsak, A Zimmer, A Malla. CB2 receptors as new therapeutic targets for liver diseases. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17952109. |
cannabinoid type-1 (cb1) and type-2 (cb2) receptors belong to the family of g protein-coupled receptors and mediate biological effects of phyto-derived and endogenous cannabinoids. |
2008-04-02 |
2023-08-12 |
Not clear |
| N Rimmerman, H V Hughes, H B Bradshaw, M X Pazos, K Mackie, A L Prieto, J M Walke. Compartmentalization of endocannabinoids into lipid rafts in a dorsal root ganglion cell line. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17965731. |
n-arachidonoyl ethanolamine (aea) and 2-arachidonoyl glycerol (2-ag) are endogenous cannabinoids binding to the cannabinoid receptors cb1 and cb2 to modulate neuronal excitability and synaptic transmission in primary afferent neurons. |
2008-04-02 |
2023-08-12 |
Not clear |
| C-L Chin, A E Tovcimak, V P Hradil, T R Seifert, P R Hollingsworth, P Chandran, C Z Zhu, D Gauvin, M Pai, J Wetter, G C Hsieh, P Honore, J M Frost, M J Dart, M D Meyer, B B Yao, B F Cox, G B Fo. Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17965748. |
activation of cannabinoid cb1 and/or cb2 receptors mediates analgesic effects across a broad spectrum of preclinical pain models. |
2008-04-02 |
2023-08-12 |
rat |
| A Poso, J W Huffma. Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17982473. |
targeting the cannabinoid cb2 receptor: modelling and structural determinants of cb2 selective ligands. |
2008-04-02 |
2023-08-12 |
Not clear |
| J J McDougall, V Yu, J Thomso. In vivo effects of CB2 receptor-selective cannabinoids on the vasculature of normal and arthritic rat knee joints. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17982474. |
in vivo effects of cb2 receptor-selective cannabinoids on the vasculature of normal and arthritic rat knee joints. |
2008-04-02 |
2023-08-12 |
rat |
| M Rajesh, P Mukhopadhyay, G Haskó, J W Huffman, K Mackie, P Pache. CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17994109. |
cannabinoids may modulate cell proliferation in various cell types through cannabinoid 2 (cb2) receptors. |
2008-04-02 |
2023-08-12 |
human |
| M Maccarron. Good news for CB1 receptors: endogenous agonists are in the right place. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17994111. |
endocannabinoids are endogenous ligands of brain-type (cb1) and spleen-type (cb2) cannabinoid receptors. |
2008-04-02 |
2023-08-12 |
Not clear |
| B B Yao, G C Hsieh, J M Frost, Y Fan, T R Garrison, A V Daza, G K Grayson, C Z Zhu, M Pai, P Chandran, A K Salyers, E J Wensink, P Honore, J P Sullivan, M J Dart, M D Meye. In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17994110. |
in vitro and in vivo characterization of a-796260: a selective cannabinoid cb2 receptor agonist exhibiting analgesic activity in rodent pain models. |
2008-04-02 |
2023-08-12 |
Not clear |
| B B Yao, G C Hsieh, J M Frost, Y Fan, T R Garrison, A V Daza, G K Grayson, C Z Zhu, M Pai, P Chandran, A K Salyers, E J Wensink, P Honore, J P Sullivan, M J Dart, M D Meye. In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17994110. |
selective cannabinoid cb2 receptor agonists have demonstrated analgesic activity across multiple preclinical pain models. |
2008-04-02 |
2023-08-12 |
Not clear |